Patient, disease, and treatment characteristics
| Characteristic . | N = 691 . |
|---|---|
| Age | |
| Median (IQR) | 61 (51-68) |
| Range | 19-84 |
| Sex | |
| Male | 437 (63%) |
| Female | 254 (37%) |
| Race | |
| White | 583 (84%) |
| Asian | 58 (8%) |
| Black or African American | 18 (3%) |
| American Indian or Alaska Native | 13 (2%) |
| Multiple | 8 (1%) |
| Unknown | 7 (1%) |
| Native Hawaiian or other Pacific Islander | 4 (1%) |
| Ethnicity | |
| Not Hispanic or Latino | 629 (91%) |
| Hispanic or Latino | 52 (8%) |
| Unknown | 10 (1%) |
| Prior HCT | 234 (34%) |
| Disease | |
| Aggressive NH∗ | 318 (46%) |
| Multiple myeloma/plasma cell leukemia | 120 (17%) |
| Other indolent NHL† | 117 (17%) |
| ALL‡ | 99 (14%) |
| MCL | 37 (5%) |
| Bone marrow involvement by morphology, %§ | |
| Median (IQR) | 0 (0-30) |
| Range | 0-100 |
| Missing | 267 |
| Bone marrow involvement by flow cytometry, %§ | |
| Median (IQR) | 0 (0-19) |
| Range | 0-99 |
| Missing | 252 |
| Received bridging therapy|| | 422 (61%) |
| Aggressive NHL | 153 (48%) |
| Multiple myeloma/plasma cell leukemia | 108 (90%) |
| Other indolent NHL | 69 (59%) |
| ALL | 59 (60%) |
| MCL | 33 (89%) |
| LD regimen | |
| Low-intensity Cy/Flu | 403 (58%) |
| High-intensity Cy/Flu | 253 (37%) |
| Other¶ | 35 (5%) |
| Total CAR T-cell dose, × 106cells | |
| Median (IQR) | 170 (111-402) |
| Range | 5-43 692 |
| CAR T-cell product | |
| CD19 targeted | |
| JCAR014# | 193 (28%) |
| Axicabtagene ciloleucel | 140 (20%) |
| Lisocabtagene maraleucel | 87 (13%) |
| Brexucabtagene autoleucel | 47 (7%) |
| JCAR021# | 44 (6%) |
| Tisagenlecleucel | 15 (2%) |
| CD20 targeted | |
| Investigational product∗∗ | 45 (7%) |
| BCMA targeted | |
| Ciltacabtagene autoleucel | 52 (8%) |
| Investigational product# | 38 (5%) |
| Idecabtagene vicleucel | 30 (4%) |
| CAR T-cell product category | |
| Investigational CAR T-cell product with 4-1BB costimulatory domain†† | 320 (46%) |
| Commercial CD19-targeted CAR T-cell product with CD28 costimulatory domain | 187 (27%) |
| Commercial CD19-targeted CAR T-cell product with 4-1BB costimulatory domain | 102 (15%) |
| Commercial BCMA-targeted CAR T-cell product | 82 (12%) |
| Pre-LD ANC, ×103cells per μL | |
| Median (IQR) | 2.84 (1.79-4.29) |
| Range | 0.00-54.03 |
| Missing | 1 |
| Pre-LD Hb (g/dL) | |
| Median (IQR) | 10.70 (9.50-12.35) |
| Range | 7.00-17.10 |
| Pre-LD platelet count, × 103/μL | |
| Median (IQR) | 142 (89-202) |
| Range | 6-790 |
| Characteristic . | N = 691 . |
|---|---|
| Age | |
| Median (IQR) | 61 (51-68) |
| Range | 19-84 |
| Sex | |
| Male | 437 (63%) |
| Female | 254 (37%) |
| Race | |
| White | 583 (84%) |
| Asian | 58 (8%) |
| Black or African American | 18 (3%) |
| American Indian or Alaska Native | 13 (2%) |
| Multiple | 8 (1%) |
| Unknown | 7 (1%) |
| Native Hawaiian or other Pacific Islander | 4 (1%) |
| Ethnicity | |
| Not Hispanic or Latino | 629 (91%) |
| Hispanic or Latino | 52 (8%) |
| Unknown | 10 (1%) |
| Prior HCT | 234 (34%) |
| Disease | |
| Aggressive NH∗ | 318 (46%) |
| Multiple myeloma/plasma cell leukemia | 120 (17%) |
| Other indolent NHL† | 117 (17%) |
| ALL‡ | 99 (14%) |
| MCL | 37 (5%) |
| Bone marrow involvement by morphology, %§ | |
| Median (IQR) | 0 (0-30) |
| Range | 0-100 |
| Missing | 267 |
| Bone marrow involvement by flow cytometry, %§ | |
| Median (IQR) | 0 (0-19) |
| Range | 0-99 |
| Missing | 252 |
| Received bridging therapy|| | 422 (61%) |
| Aggressive NHL | 153 (48%) |
| Multiple myeloma/plasma cell leukemia | 108 (90%) |
| Other indolent NHL | 69 (59%) |
| ALL | 59 (60%) |
| MCL | 33 (89%) |
| LD regimen | |
| Low-intensity Cy/Flu | 403 (58%) |
| High-intensity Cy/Flu | 253 (37%) |
| Other¶ | 35 (5%) |
| Total CAR T-cell dose, × 106cells | |
| Median (IQR) | 170 (111-402) |
| Range | 5-43 692 |
| CAR T-cell product | |
| CD19 targeted | |
| JCAR014# | 193 (28%) |
| Axicabtagene ciloleucel | 140 (20%) |
| Lisocabtagene maraleucel | 87 (13%) |
| Brexucabtagene autoleucel | 47 (7%) |
| JCAR021# | 44 (6%) |
| Tisagenlecleucel | 15 (2%) |
| CD20 targeted | |
| Investigational product∗∗ | 45 (7%) |
| BCMA targeted | |
| Ciltacabtagene autoleucel | 52 (8%) |
| Investigational product# | 38 (5%) |
| Idecabtagene vicleucel | 30 (4%) |
| CAR T-cell product category | |
| Investigational CAR T-cell product with 4-1BB costimulatory domain†† | 320 (46%) |
| Commercial CD19-targeted CAR T-cell product with CD28 costimulatory domain | 187 (27%) |
| Commercial CD19-targeted CAR T-cell product with 4-1BB costimulatory domain | 102 (15%) |
| Commercial BCMA-targeted CAR T-cell product | 82 (12%) |
| Pre-LD ANC, ×103cells per μL | |
| Median (IQR) | 2.84 (1.79-4.29) |
| Range | 0.00-54.03 |
| Missing | 1 |
| Pre-LD Hb (g/dL) | |
| Median (IQR) | 10.70 (9.50-12.35) |
| Range | 7.00-17.10 |
| Pre-LD platelet count, × 103/μL | |
| Median (IQR) | 142 (89-202) |
| Range | 6-790 |
JCAR014, investigational CAR T-cell product containing 4-1BB costimulatory domain, murine CD19-targeted single-chain variable fragment (scFv), and infused as 1:1 ratio of CD4+:CD8+ CAR T cells; JCAR021, investigational CAR T-cell product containing 4-1BB costimulatory domain, fully human CD19-targeted scFv, and infused as 1:1 ratio of CD4+:CD8+ CAR T cells.
BCMA, B-cell maturation antigen; Hb, hemoglobin; IQR, interquartile range; LD, lymphodepletion.
Large B-cell lymphoma, Burkitt lymphoma, central nervous system lymphoma, pleiomorphic MCL.
Follicular lymphoma, chronic lymphocytic leukemia, marginal zone lymphoma, Waldenstrom macroglobulinemia, hairy cell leukemia.
Including 1 patient with lymphoid blast phase of chronic myeloid leukemia.
Performed within 30 days of CAR T-cell infusion; for patients with ALL, the Children’s Oncology Group (COG) result was used.
Any antineoplastic therapy administered after leukapheresis and before lymphodepletion, including corticosteroids, intrathecal chemotherapy, and radiation therapy; percentages of patients receiving bridging therapy within each disease type are calculated from the total number of patients with the respective disease type.
Other LD regimens included single-agent cyclophosphamide (n = 20), single-agent bendamustine (n = 6), cyclophosphamide/etoposide ± dexamethasone (n = 8), and single-agent fludarabine (n = 1).
Contained a 4-1BB costimulatory domain.
Contained a dual 4-1BB and CD28 costimulatory domain.
Including the 45 patients who received the investigational CD20-targeted CAR T-cell product containing both 4-1BB and CD28 costimulatory domains.